GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » REMSleep Holdings Inc (OTCPK:RMSL) » Definitions » EBITDA

RMSL (REMSleep Holdings) EBITDA : $-1.59 Mil (TTM As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is REMSleep Holdings EBITDA?

REMSleep Holdings's EBITDA for the three months ended in Sep. 2024 was $-0.20 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.59 Mil.

During the past 3 years, the average EBITDA Growth Rate was -48.00% per year. During the past 5 years, the average EBITDA Growth Rate was -19.60% per year. During the past 10 years, the average EBITDA Growth Rate was -22.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of REMSleep Holdings was 83.10% per year. The lowest was -800.10% per year. And the median was -52.30% per year.

REMSleep Holdings's EBITDA per Share for the three months ended in Sep. 2024 was $0.00. Its EBITDA per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.00.

During the past 3 years, the average EBITDA per Share Growth Rate was 20.60% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 62.80% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 55.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of REMSleep Holdings was 97.70% per year. The lowest was -92.00% per year. And the median was 63.00% per year.


REMSleep Holdings EBITDA Historical Data

The historical data trend for REMSleep Holdings's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

REMSleep Holdings EBITDA Chart

REMSleep Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.47 -0.52 -2.85 -1.19 -1.67

REMSleep Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.25 -1.02 -0.20 -0.17 -0.20

Competitive Comparison of REMSleep Holdings's EBITDA

For the Medical Devices subindustry, REMSleep Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


REMSleep Holdings's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, REMSleep Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where REMSleep Holdings's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

REMSleep Holdings's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

REMSleep Holdings's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, REMSleep Holdings's EBITDA was $-1.67 Mil.

REMSleep Holdings's EBITDA for the quarter that ended in Sep. 2024 is calculated as

REMSleep Holdings's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Sep. 2024, REMSleep Holdings's EBITDA was $-0.20 Mil.

EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

REMSleep Holdings  (OTCPK:RMSL) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


REMSleep Holdings EBITDA Related Terms

Thank you for viewing the detailed overview of REMSleep Holdings's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


REMSleep Holdings Business Description

Traded in Other Exchanges
N/A
Address
14175 ICOT Boulevard, Suite 300, Clearwater, FL, USA, 33760
REMSleep Holdings Inc is focused on designing and manufacturing devices and products for the treatment of sleep apnea and other respiratory conditions. The group offers the product DeltaWave which is specifically designed with airflow characteristics to enable patients with sleep apnea to breathe normally. Geographically, the business activity of the group functions through the region of the United States.
Executives
Russell Finlay Bird 10 percent owner, officer: President 722 50TH STREET, DES MOINES IA 50312
Tom J Wood director, officer: CEO 1170 CHERRYWOOD RD, WAYCROSS GA 31503
Thomas Brookes director, officer: VP & MD OF EKOM EYA MINE DIV. 1149 TOPSAIL ROAD, MOUNT PEARL A4 AIN 5G2
Matthew Sullivan director, officer: ASST. VP OF EKOM EYA MINE DIV. 1149 TOPSAIL ROAD, MOUNT PEARL A4 AIN5G2
David M Barnes officer: Chief Financial Officer 6800 JERICHO TURNPIKE, SUITE 208E, SYOSSET NY 11791
Walter Leslie Thistle director, other: Chairman of the Board 17 COLLINGWOOD CRESCENT, MOUNT PEARL A4 A1N5C6
Kat Exploration Inc. 10 percent owner 1149 TOPSAIL ROAD, MOUNT PEARL A4 A1N5G2
Ken Stead director, 10 percent owner, officer: CEO and President 15 BLADE CRESCENT, MOUNT PEARL A4 A1N 5L1
Ronald Davis officer: PRESIDENT 4412 8TH STREET SW, VERO BEACH FL 32968

REMSleep Holdings Headlines

From GuruFocus

REMSleep 510K Submission

By Marketwired Marketwired 07-15-2021

REMSleep Patent Application

By Marketwired Marketwired 11-20-2020

REMSleep 510K

By Marketwired Marketwired 06-02-2021

REMSleep Holdings, Inc. Shareholder Update

By Marketwired 11-15-2024

RemSleep Holdings Provides a Corporate Update on Testing

By Value_Insider Value_Insider 11-08-2022

Condensation Testing Per ISO 18562-4:2017

By GuruFocusNews GuruFocusNews 01-05-2022

REMSleep Holdings Patent Status

By GlobeNewswire 03-06-2024

RemSleep Holdings Inc. Issues Letter to Shareholders

By Stock market mentor Stock market mentor 01-06-2023